Market Cap
$254.9M
AKBA
Akebia Therapeutics, Inc.
$0.8650 ▼ -0.69%
Prev close $0.8710Market cap$254.9M
ConsensusStrong Buy
12-mo target$3.92 (+352.8%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (6 insiders)High Impact Filing (7/10)27 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on AKBA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
50 funds
Inst. Value
$109.0M
Inst. Activity
27 buys / 13 sells
Insider Activity
$86.6K buy / $963.0K sell
Insider Net $
-$876.4K
Social Sentiment
75° Bullish
SEC Reports
3
Price chart 30d -12.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a bio
Aug 6, 2026 Insider
Jun 30, 2026 SEC Butler John P. acquired via exercise 350,000 shares
CEO and President @ $0.6300 ($220.5K)
Akebia Therapeutics and U.S. Renal Care announced that the VOICE trial (Vafseo vs. ESA in 2,116 dialysis patients) met i
8-K — Impact 7/10
Jun 30, 2026 Inst.
STATE STREET CORP — TRIM
5,390,853 shares ($6.1M)
Jun 30, 2026 Inst.
JACOBS LEVY EQUITY MANAGEMENT, — DOUBLED
4,273,026 shares ($4.9M)
Jun 29, 2026 Insider
Ostrowski Erik sold 56,019 shares
SVP, CFO, CBO & Treasurer @ $1.11 ($62.2K)
Jun 17, 2026 Insider
Apr 30, 2026 SEC ADAMS ADRIAN was granted 53,600 shares
Director
Akebia Therapeutics reported Q4 2025 EPS of $-0.05, a 900% miss vs consensus of $-0.01, with revenue of $51.7M in line w
PRESS-RELEASE — Impact 7/10
Analyst ratings buy % -9.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 15, 2026 | BTIG | REITERATE | Buy | 53% |
| Sep 8, 2026 | WestPark Capital | INITIATE | Buy | 52% |
| Aug 8, 2026 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Jul 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 7, 2026 | BTIG | REITERATE | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Aug 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% |
Price targets
Where 6 covering analysts think AKBA trades over the next 12 months.
$3.92 +352.8% upside Strong Buy
Current$0.8650 Low$1.00 Median$4.00 High$6.00 6 analysts
$1.00$6.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
75°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 0 neutral · avg impact 7.0/10.
BULLISH8-K7/10
Akebia Therapeutics and U.S. Renal Care announced that the VOICE trial (Vafseo vs. ESA in 2,116 dial
Jun 30, 2026
BEARISHPRESS-RELEASE7/10
Akebia Therapeutics reported Q4 2025 EPS of $-0.05, a 900% miss vs consensus of $-0.01, with revenue
Apr 30, 2026
BULLISH8-K7/10
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues
Feb 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better
Oct 1, 2026
short_volume
Short Volume: AKBA — 69.3% short (2.3M / 3.4M)
Short: 2,327,455 | Exempt: 2,500 | TRF Vol: 3,360,072 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: AKBA — 60.8% short (5.4M / 8.9M)
Short: 5,400,036 | Exempt: 32,939 | TRF Vol: 8,887,208 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: AKBA — 63.5% short (1.6M / 2.6M)
Short: 1,649,219 | Exempt: 46,500 | TRF Vol: 2,596,373 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: AKBA — 71.8% short (1.8M / 2.6M)
Short: 1,847,014 | Exempt: 0 | TRF Vol: 2,573,597 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.03 | $-0.04–$-0.02 | 0.0% | +25.0% | 1↑ 0↓ | $0.0B | 2 |
| Next Q | $-0.03 | $-0.05–$-0.01 | 40.0% | -50.0% | 0↑ 1↓ | $0.0B | 2 |
| Current FY | $-0.16 | $-0.16–$-0.16 | -700.0% | -52.4% | 0↑ 1↓ | $0.2B | 1 |
| Next FY | $-0.36 | $-0.39–$-0.33 | -125.0% | -80.0% | 0↑ 1↓ | $0.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.030 | — |
| 7d ago | $-0.040 | +0.010 |
| 30d ago | $-0.040 | +0.010 |
| 60d ago | $-0.030 | — |
| 90d ago | $-0.030 | — |
Institutional ownership
Which big funds own AKBA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $109.0M total value (95,501,664 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, AQR. Net buying activity: 27 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 19,986,374 | $22.8M | 20.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 11,322,143 | $12.9M | 11.8% | — |
| AQR CAPITAL MANAGEMENT LLC | 9,151,524 | $10.4M | 9.6% | DOUBLED +177.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 6,727,302 | $7.7M | 7.0% | — |
| STATE STREET CORP | 5,390,853 | $6.1M | 5.6% | TRIM -53.6% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 4,273,026 | $4.9M | 4.5% | DOUBLED +894.5% |
| GOLDMAN SACHS GROUP INC | 3,689,167 | $4.2M | 3.9% | — |
| MILLENNIUM MANAGEMENT LLC | 3,196,605 | $3.6M | 3.3% | ADD +34.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,533,977 | $2.9M | 2.7% | — |
| TWO SIGMA INVESTMENTS, LP | 2,436,673 | $2.8M | 2.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | TRIM | 11,614,006 | 5,390,853 | -53.6% | $6.1M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | DOUBLED | 429,669 | 4,273,026 | +894.5% | $4.9M |
| MILLENNIUM MANAGEMENT LLC | ADD | 2,384,713 | 3,196,605 | +34.0% | $3.6M |
| FMR LLC | ADD | 1,335,328 | 1,871,059 | +40.1% | $2.1M |
| Qube Research & Technologies Ltd | TRIM | 2,395,215 | 1,779,707 | -25.7% | $2.0M |
| UBS Group AG | ADD | 769,471 | 1,374,950 | +78.7% | $1.6M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,833,128 | 1,223,963 | -33.2% | $1.4M |
| CITIGROUP INC | TRIM | 2,854,586 | 1,124,570 | -60.6% | $1.3M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 10,391 | 626,160 | +5926.0% | $713.8K |
| Creative Planning | DOUBLED | 176,566 | 545,740 | +209.1% | $622.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 44 transactions. Net -$876.4K — $86.6K bought, $963.0K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Butler John P. | CEO and President | EXERCISE | 350,000 | $0.6300 | $220.5K |
| Jun 29, 2026 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | SELL | 56,019 | $1.11 | $62.2K |
| Jun 17, 2026 | ADAMS ADRIAN | Director | AWARD | 53,600 | — | — |
| Jun 17, 2026 | ZUMWALT LEANNE M | Director | AWARD | 35,700 | — | — |
| Jun 17, 2026 | ADAMS ADRIAN | Director | AWARD | 35,700 | — | — |
| Jun 17, 2026 | ZUMWALT LEANNE M | Director | AWARD | 53,600 | — | — |
| Jun 17, 2026 | FRIESON RON | Director | AWARD | 35,700 | — | — |
| Jun 17, 2026 | FRIESON RON | Director | AWARD | 53,600 | — | — |
| Jun 17, 2026 | ROGERS MICHAEL W | Director | AWARD | 35,700 | — | — |
| Jun 17, 2026 | ROGERS MICHAEL W | Director | AWARD | 53,600 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AKBA.
Shares short
20,504,915
Settlement Sep 15, 2026
Change vs prior
-10.9%
Semi-monthly cycle
Days to cover
2.8
At avg daily volume
Of shares outstanding
≈7.4%
Estimate — not % of float
All AKBA filing & press-release reports (3)
- 8-K reportJun 30, 2026
- PRESS-RELEASE reportApr 30, 2026
- 8-K reportFeb 26, 2026